Table 4 Multinomial logistic regression showing whether FGF21 was an independent influencing factor for CAS and HP

Model 1

FGF21^*

2.066 (1.543–2.766)

< 0.001

6.311 (4.251–9.37)

< 0.001

Age

1.091 (1.064–1.118)

< 0.001

1.142 (1.105–1.181)

< 0.001

Gender

2.115 (1.294–3.458)

0.003

4.141 (2.257–7.597)

< 0.001

T2DM duration

1.001 (0.998–1.004)

0.422

1.005 (1.002–1.008)

0.003

BMI

1.058 (0.988–1.132)

0.105

1.125 (1.037–1.22)

0.005

SBP

1.02 (1.003–1.038)

0.024

1.042 (1.021–1.062)

< 0.001

DBP

0.984 (0.957–1.012)

0.261

0.977 (0.945–1.009)

0.163

Smoking

1.642 (1.069–2.522)

0.024

1.42 (0.84–2.4)

0.191

Drinking

0.678 (0.434–1.06)

0.088

0.983 (0.56–1.725)

0.952

Model 2

FGF21^*

1.855 (1.428–2.41)

< 0.001

4.763 (3.281–6.915)

< 0.001

Antihypertensive therapy

0.29 (0.156–0.54)

< 0.001

0.071 (0.038–0.133)

< 0.001

Antidiabetic therapy

No

0.379 (0.062–2.303)

0.292

1.625 (0.104–25.353)

0.729

Insulin

0.242 (0.036–1.637)

0.146

1.806 (0.102–31.877)

0.687

OHA

0.395 (0.065–2.406)

0.314

1.221 (0.078–19.049)

0.887

Insulin + OHA

0.186 (0.029–1.187)

0.075

0.437 (0.027–7.038)

0.559

Hypercholesterolemia

1.466 (0.659–3.262)

0.349

1.046 (0.413–2.65)

0.924

Hypotriglyceridemia

1.088 (0.5-2.368)

0.831

1.317 (0.52–3.335)

0.561

Lipid-lowering therapy

0.913 (0.384–2.168)

0.836

0.727 (0.261–2.027)

0.542

Model 3

FGF21^*

5.068 (2.573–9.985)

< 0.001

4.984 (2.530–9.815)

< 0.001

FPG^*

1.115 (0.251–4.967)

0.886

0.120 (0.016–0.899)

0.039

HbA1c^*

0.401 (0.048–3.333)

0.398

0.054 (0.002–1.304)

0.072

SBP

1.030 (1.014–1.047)

< 0.001

1.063 (1.039–1.087)

< 0.001

DBP

0.966 (0.941–0.992)

0.010

0.966 (0.932–1.002)

0.063

TG^*

0.779 (0.196–3.093)

0.723

1.015 (0.151–6.839)

0.988

TC^*

0.816 (0.002-308.053)

0.948

1.377(0.001-1664.835)

0.636

HDL-c^*

0.250 (0.017–3.643)

0.392

0.063 (0.002–2.202)

0.128

LDL-c^*

1.126 (0.033–38.203)

0.843

0.587 (0.009–38.282)

0.803

ALT^*

0.284 (0.109–0.738)

0.010

0.262 (0.070–0.980)

0.047

AST^*

9.050 (1.100-74.469)

0.041

7.813 (0.450-135.588)

0.158

ALP^*

1.526 (0.223–10.457)

0.667

0.785 (0.002–1.304)

0.859

eGFR^*

0.094 (0.021–0.427)

0.002

0.021 (0.004–0.107)

< 0.001

Full model

FGF21^*

4.600 (2.225–9.510)

< 0.001

4.601 (2.225–9.510)

< 0.001

Age

1.104 (1.073–1.135)

< 0.001

1.191 (1.129–1.257)

< 0.001

Gender

2.119 (1.276–3.519)

0.004

4.907 (2.115–11.387)

< 0.001

T2DM duration

1.000 (0.996–1.003)

0.873

1.001 (0.995–1.007)

0.798

BMI

1.041 (0.968–1.121)

0.278

1.111 (0.986–1.251)

0.083

SBP

1.011 (0.998–1.023)

0.095

1.034 (1.014–1.055)

0.001

FPG

1.438 (0.344–6.019)

0.619

0.530 (0.052–5.379)

0.591

Smoking

1.301 (0.842–2.011)

0.236

1.151 (0.562–2.358)

0.701

Antihypertensive therapy

0.302 (0.147–0.623)

0.001

2.679(0.436–16.457)

0.001

ALT^*

0.713 (0.427–1.192)

0.197

0.806 (0.317–2.054)

0.652

eGFR^*

12.801(0.259-632.546)

0.200

19.983(0.091-4398.562)

0.277